162 related articles for article (PubMed ID: 37918792)
1. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
[TBL] [Abstract][Full Text] [Related]
2. Systems pharmacodynamic model of combined gemcitabine and trabectedin in pancreatic cancer cells. Part I.Çô Effects on signal transduction pathways related to tumor growth.
Miao X; Shen S; Koch G; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):214-227. PubMed ID: 38498417
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.
Miao X; Koch G; Straubinger RM; Jusko WJ
Cancer Chemother Pharmacol; 2016 Jan; 77(1):181-93. PubMed ID: 26604207
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.
Miao X; Koch G; Ait-Oudhia S; Straubinger RM; Jusko WJ
Front Pharmacol; 2016; 7():421. PubMed ID: 27895579
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.
Hamed SS; Straubinger RM; Jusko WJ
Cancer Chemother Pharmacol; 2013 Sep; 72(3):553-63. PubMed ID: 23835677
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.
Zhu X; Straubinger RM; Jusko WJ
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):477-96. PubMed ID: 26252969
[TBL] [Abstract][Full Text] [Related]
7. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.
Niu J; Wang X; Qu J; Mager DE; Straubinger RM
BMC Cancer; 2020 Oct; 20(1):1024. PubMed ID: 33097020
[TBL] [Abstract][Full Text] [Related]
9. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.
Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):549-561. PubMed ID: 30084546
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
Fiorini C; Cordani M; Padroni C; Blandino G; Di Agostino S; Donadelli M
Biochim Biophys Acta; 2015 Jan; 1853(1):89-100. PubMed ID: 25311384
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
[TBL] [Abstract][Full Text] [Related]
16. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.
Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
Front Pharmacol; 2018; 9():84. PubMed ID: 29520231
[TBL] [Abstract][Full Text] [Related]
17. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
19. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer.
Lin Q; Shen S; Qian Z; Rasam SS; Serratore A; Jusko WJ; Kandel ES; Qu J; Straubinger RM
Mol Cell Proteomics; 2022 Oct; 21(10):100409. PubMed ID: 36084875
[TBL] [Abstract][Full Text] [Related]
20. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
